Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

NCT03053050 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03053050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03053050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Terminated
Start date
February 13, 2017
Completion date
June 19, 2019
Enrollment
808 (actual)
Sites
298

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis